Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen.
Helland T, Naume B, Hustad S, Bifulco E, Kvaløy JT, Saetersdal AB, Synnestvedt M, Lende TH, Gilje B, Mjaaland I, Weyde K, Blix ES, Wiedswang G, Borgen E, Hertz DL, Janssen EAM, Mellgren G, Søiland H. Helland T, et al. Among authors: blix es. Mol Oncol. 2021 Apr;15(4):957-967. doi: 10.1002/1878-0261.12865. Epub 2020 Dec 14. Mol Oncol. 2021. PMID: 33252186 Free PMC article.
Internal and external validation of an ESTRO delineation guideline - dependent automated segmentation tool for loco-regional radiation therapy of early breast cancer.
Eldesoky AR, Yates ES, Nyeng TB, Thomsen MS, Nielsen HM, Poortmans P, Kirkove C, Krause M, Kamby C, Mjaaland I, Blix ES, Jensen I, Berg M, Lorenzen EL, Taheri-Kadkhoda Z, Offersen BV. Eldesoky AR, et al. Among authors: blix es. Radiother Oncol. 2016 Dec;121(3):424-430. doi: 10.1016/j.radonc.2016.09.005. Epub 2016 Sep 30. Radiother Oncol. 2016. PMID: 27697296
Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1.
Francolini G, Thomsen MS, Yates ES, Kirkove C, Jensen I, Blix ES, Kamby C, Nielsen MH, Krause M, Berg M, Mjaaland I, Schreiber A, Kasti UM, Boye K, Offersen BV. Francolini G, et al. Among authors: blix es. Radiother Oncol. 2017 May;123(2):282-287. doi: 10.1016/j.radonc.2017.03.011. Epub 2017 Mar 25. Radiother Oncol. 2017. PMID: 28351523 Clinical Trial.
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE. Eikesdal HP, et al. Among authors: blix es. Ann Oncol. 2021 Feb;32(2):240-249. doi: 10.1016/j.annonc.2020.11.009. Epub 2020 Nov 24. Ann Oncol. 2021. PMID: 33242536 Free article. Clinical Trial.
A national precision cancer medicine implementation initiative for Norway.
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium; Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R; InPreD-Norway and National Molecular Tumor Board Consortium; IMPRESS-Norway Consortium; Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å. Taskén K, et al. Among authors: blix es. Nat Med. 2022 May;28(5):885-887. doi: 10.1038/s41591-022-01777-4. Nat Med. 2022. PMID: 35513529 No abstract available.
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D, Hjortland GO, Hovig E, Hovland R, Iversen AC, Janssen E, Kyte JA, von der Lippe Gythfeldt H, Lothe R, Lund JÅ, Meza-Zepeda L, Munthe-Kaas MC, Nguyen OTD, Niehusmann P, Nilsen H, Puco K, Ree AH, Riste TB, Semb K, Steinskog ESS, Stensvold A, Suhrke P, Tennøe Ø, Tjønnfjord GE, Vassbotn LJ, Aas E, Aasebø K, Tasken K, Smeland S. Helland Å, et al. J Transl Med. 2022 May 14;20(1):225. doi: 10.1186/s12967-022-03432-5. J Transl Med. 2022. PMID: 35568909 Free PMC article. Clinical Trial.
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.
Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D, Hjortland GO, Hovig E, Hovland R, Iversen AC, Janssen E, Kyte JA, von der Lippe Gythfeldt H, Lothe R, Lund JÅ, Meza-Zepeda L, Munthe-Kaas MC, Nguyen OTD, Niehusmann P, Nilsen H, Puco K, Ree AH, Riste TB, Semb K, Steinskog ESS, Stensvold A, Suhrke P, Tennøe Ø, Tjønnfjord GE, Vassbotn LJ, Aas E, Aasebø K, Tasken K, Smeland S. Helland Å, et al. J Transl Med. 2022 Jul 15;20(1):317. doi: 10.1186/s12967-022-03518-0. J Transl Med. 2022. PMID: 35841045 Free PMC article. No abstract available.
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.
Yndestad S, Engebrethsen C, Herencia-Ropero A, Nikolaienko O, Vintermyr OK, Lillestøl RK, Minsaas L, Leirvaag B, Iversen GT, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Aase HS, Aas T, Gudlaugsson EG, Llop-Guevara A, Serra V, Janssen EAM, Lønning PE, Knappskog S, Eikesdal HP. Yndestad S, et al. Among authors: blix es. JCO Precis Oncol. 2023 Sep;7:e2300338. doi: 10.1200/PO.23.00338. JCO Precis Oncol. 2023. PMID: 38039432 Free PMC article.
19 results